Literature DB >> 11085324

Pharmacology of MDMA in humans.

M Farré, P N Roset, C H Lopez, M Mas, J Ortuño, E Menoyo, N Pizarro, J Segura, J Cami.   

Abstract

MDMA given at recreational doses (range tested 50 to 150 mg) to healthy volunteers, produced mydriasis and marked increases in systolic and diastolic blood pressure, heart rate, and pupillary diameter. MDMA induced changes on oral temperature. The time course of this observation was biphasic, as a slight decrease at 1 h and a slight increase at 2 and 4 h were observed. MDMA induced a slight dose-dependent impairment on psychomotor performance. MDMA produced a marked rise in plasma cortisol and prolactin concentrations. The elimination half-life of MDMA was about 8-9 h. Drug concentrations increased, and a parallel increase in physiologic and hormonal measures was observed. Both peak concentrations and peak effects were obtained between 1 and 2 h and decreased to baseline values 4-6 h after drug administration.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11085324     DOI: 10.1111/j.1749-6632.2000.tb05199.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  37 in total

1.  Ecstasy (MDMA) Alters Cardiac Gene Expression and DNA Methylation: Implications for Circadian Rhythm Dysfunction in the Heart.

Authors:  Christopher A Koczor; Ivan Ludlow; Robert S Hight; Zhe Jiao; Earl Fields; Tomika Ludaway; Rodney Russ; Rebecca A Torres; William Lewis
Journal:  Toxicol Sci       Date:  2015-08-06       Impact factor: 4.849

2.  Metabolism and disposition of 3,4-methylenedioxymethamphetamine ("ecstasy") in baboons after oral administration: comparison with humans reveals marked differences.

Authors:  Melanie Mueller; Amy K Goodwin; Nancy A Ator; Una D McCann; George A Ricaurte
Journal:  J Pharmacol Exp Ther       Date:  2011-04-14       Impact factor: 4.030

Review 3.  Drugs and HPA axis.

Authors:  Alberto Giacinto Ambrogio; Francesca Pecori Giraldi; Francesco Cavagnini
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 4.  Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.

Authors:  Lee E Dunlap; Anne M Andrews; David E Olson
Journal:  ACS Chem Neurosci       Date:  2018-07-12       Impact factor: 4.418

5.  MDMA does not alter responses to the Trier Social Stress Test in humans.

Authors:  Anya K Bershad; Melissa A Miller; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2017-04-21       Impact factor: 4.530

6.  Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics.

Authors:  M Farré; R de la Torre; B O Mathúna; P N Roset; A M Peiró; M Torrens; J Ortuño; M Pujadas; J Camí
Journal:  Psychopharmacology (Berl)       Date:  2004-04-08       Impact factor: 4.530

7.  Human Pharmacology of Mephedrone in Comparison with MDMA.

Authors:  Esther Papaseit; Clara Pérez-Mañá; Julián-Andrés Mateus; Mitona Pujadas; Francina Fonseca; Marta Torrens; Eulàlia Olesti; Rafael de la Torre; Magí Farré
Journal:  Neuropsychopharmacology       Date:  2016-05-20       Impact factor: 7.853

8.  Microinjection of muscimol into the dorsomedial hypothalamus suppresses MDMA-evoked sympathetic and behavioral responses.

Authors:  Daniel E Rusyniak; Maria V Zaretskaia; Dmitry V Zaretsky; Joseph A DiMicco
Journal:  Brain Res       Date:  2008-06-14       Impact factor: 3.252

9.  3,4-Methylenedioxymethamphetamine (MDMA) and metabolites disposition in blood and plasma following controlled oral administration.

Authors:  Rebecca L Hartman; Nathalie A Desrosiers; Allan J Barnes; Keming Yun; Karl B Scheidweiler; Erin A Kolbrich-Spargo; David A Gorelick; Robert S Goodwin; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2013-11-15       Impact factor: 4.142

Review 10.  A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities.

Authors:  Fabrizio Schifano
Journal:  Psychopharmacology (Berl)       Date:  2003-12-13       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.